Treatment for Pulmonary Hypertension of Left Heart Disease

about

Clinical Characteristics and Treatment of Cardiomyopathies in Children.Hypoxic Pulmonary Vasoconstriction in Humans: Tale or Myth.Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease.

P2860

Q36886275-FFEF8B91-6058-4591-B539-7BD19BDB9710 Q39143610-62FA500E-5BE3-4A29-8521-DC11107F3D88 Q42782025-A5193619-F3A8-486D-8F10-D0CDB8722CF7

P2860

Treatment for Pulmonary Hypertension of Left Heart Disease

Item

http://www.wikidata.org/entity/Q56796423

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в червні 2012

@uk

name

Treatment for Pulmonary Hypertension of Left Heart Disease

@en

Treatment for Pulmonary Hypertension of Left Heart Disease

@nl

type

Item

label

Treatment for Pulmonary Hypertension of Left Heart Disease

@en

Treatment for Pulmonary Hypertension of Left Heart Disease

@nl

prefLabel

Treatment for Pulmonary Hypertension of Left Heart Disease

@en

Treatment for Pulmonary Hypertension of Left Heart Disease

@nl

P1476

Treatment for Pulmonary Hypertension of Left Heart Disease

@en

P2093

Alessandra Vitelli

http://www.w3.org/2001/XMLSchema#string

Valentina Labate

http://www.w3.org/2001/XMLSchema#string

P2860

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: de

Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension

Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.

Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study

Age-associated increases in pulmonary artery systolic pressure in the general population.

P2888

s11936-012-0185-6

P304

319-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11936-012-0185-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ross Arena

Marco Guazzi

P577

2012-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22711417

http://www.w3.org/2001/XMLSchema#string

Treatment for Pulmonary Hypertension of Left Heart Disease

about

P2860

P2860

Treatment for Pulmonary Hypertension of Left Heart Disease

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698